```
=> file caplus
FILE 'CAPLUS' ENTERED AT 14:54:32 ON 31 JAN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 31 Jan 2007  VOL 146 ISS 6
FILE LAST UPDATED: 30 Jan 2007  (20070130/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> d que
L1              STR
```




```
Structure attributes must be viewed using STN Express query preparation.
L3            6 SEA FILE=REGISTRY SSS FUL L1
L4            1 SEA FILE=CAPLUS L3


=> d l4 ibib abs hitstr

L4   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2004:756707  CAPLUS
DOCUMENT NUMBER:          141:277497
TITLE:                    Preparation of benzoylureidopyridylpiperidines for the
                          treatment of type 2 diabetes
INVENTOR(S):              Schoenafinger, Karl; Kadereit, Dieter; Defossa,
                          Elisabeth; Herling, Andreas; Klabunde, Thomas
PATENT ASSIGNEE(S):       Aventis Pharma Deutschland G.m.b.H., Germany
SOURCE:                   PCT Int. Appl., 33 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 German
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
```

WO 2004078743		A1	20040916	WO 2004-EP1735	20040221
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10309929		A1	20041202	DE 2003-10309929	20030307
DE 10309929		B4	20060223		
AU 2004218267		A1	20040916	AU 2004-218267	20040221
CA 2518322		A1	20040916	CA 2004-2518322	20040221
EP 1603895		A1	20051214	EP 2004-713467	20040221
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004008148		A	20060301	BR 2004-8148	20040221
CN 1759109		A	20060412	CN 2004-80006240	20040221
JP 2006519795		T	20060831	JP 2006-504448	20040221
US 2004266768		A1	20041230	US 2004-795863	20040308
NO 2005004418		A	20050923	NO 2005-4418	20050923
PRIORITY APPLN. INFO.:				DE 2003-10309929 A	20030307
				US 2003-487497P P	20030715
				WO 2004-EP1735 A	20040221

OTHER SOURCE(S): MARPAT 141:277497

GI



I



II



III

AB Title compds. I [R1, R2 = H, halo, alkyl, etc.; R3 = H, alkyl, O-alkyl, etc.; X = OH, O-alkyl, NH2, etc.; A, B, D, E = CH, N, with the proviso that one of A, B, D or E is N; Y = (CH2)m; m = 0-2] and their pharmaceutically acceptable salts were prepared For example, condensation of amine II, e.g., prepared from 2-chloro-3-nitropyridine in 2-steps, and

2-chloro-4-fluorobenzoylisocyanate, afforded ureidopyridylpiperidine III. In activated glycogen phosphorylase inhibition assays, 4-examples of compds. I exhibited IC50 values ranging from 0.01-3.65 μM, the IC50 value of benzoylurea III was 0.04 μM. Compds. I were claimed useful for the treatment of type 2 diabetes.

IT 758720-48-8P 758720-49-9P 758720-50-2P
758720-51-3P 758720-52-4P 758720-53-5P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of benzoylureidopyridylpiperidines for the treatment of type 2 diabetes)

RN 758720-48-8 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[[(2-chloro-4-fluorobenzoyl)amino]carbonyl]amino]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 758720-49-9 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 758720-50-2 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]-2-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 758720-51-3 CAPLUS
CN 4-Piperidinecarboxamide, 1-[3-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 758720-52-4 CAPLUS
CN 4-Piperidinecarboxamide, 1-[3-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]-2-pyridinyl]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 758720-53-5 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]-2-pyridinyl]-4-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> => file uspatall
FILE 'USPATFULL' ENTERED AT 14:55:07 ON 31 JAN 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 14:55:07 ON 31 JAN 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> d que
L1 STR



Structure attributes must be viewed using STN Express query preparation.
L3 6 SEA FILE=REGISTRY SSS FUL L1
L5 1 SEA L3

=> d l5 ibib abs hitstr

L5 ANSWER 1 OF 1 USPATFULL on STN
ACCESSION NUMBER: 2004:335674 USPATFULL
TITLE: Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use
INVENTOR(S): Schoenafinger, Karl, Alzenau, GERMANY, FEDERAL REPUBLIC OF
Kadereit, Dieter, Kelkheim, GERMANY, FEDERAL REPUBLIC OF
Defossa, Elisabeth, Idstein, GERMANY, FEDERAL REPUBLIC OF
Herling, Andreas, Bad Camberg, GERMANY, FEDERAL REPUBLIC OF
Klabunde, Thomas, Frankfurt, GERMANY, FEDERAL REPUBLIC OF
PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Frankfurt am Main, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION:	US 2004266768	A1	20041230
APPLICATION INFO.:	US 2004-795863	A1	20040308 (10)

PRIORITY INFORMATION:	NUMBER	DATE
	DE 2003-10309929	20030307
	US 2003-487497P	20030715 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ROSS J. OEHLER, AVENTIS PHARMACEUTICALS INC., ROUTE 202-206, MAIL CODE: D303A, BRIDGEWATER, NJ, 08807
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
LINE COUNT: 703
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to compounds of the formula I ##STR1##

where the radicals are as defined, and their physiologically tolerated salts. The compounds are suitable, for example, as medicaments for preventing and treating type 2 diabetes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 758720-48-8P 758720-49-9P 758720-50-2P
758720-51-3P 758720-52-4P 758720-53-5P
(preparation of benzoylureidopyridylpiperidines for the treatment of type 2 diabetes)
RN 758720-48-8 USPATFULL
CN 4-Piperidinecarboxylic acid, 1-[3-[[[(2-chloro-4-fluorobenzoyl)amino]carbonyl]amino]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 758720-49-9 USPATFULL
CN 4-Piperidinecarboxylic acid, 1-[3-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 758720-50-2 USPATFULL
CN 4-Piperidinecarboxylic acid, 1-[3-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]-2-pyridinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 758720-51-3 USPATFULL
CN 4-Piperidinecarboxamide, 1-[3-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 758720-52-4 USPATFULL
CN 4-Piperidinecarboxamide, 1-[3-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]-2-pyridinyl]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 758720-53-5 USPATFULL
CN 4-Piperidinecarboxylic acid, 1-[3-[[[(2-chloro-4,5-difluorobenzoyl)amino]carbonyl]amino]-2-pyridinyl]-4-phenyl- (9CI) (CA INDEX NAME)



=>